Key result
Banxia Baizhu Tianma Tang will be evaluated for its efficacy and safety in treating H-type hypertension in this systematic review protocol, with no clinical results currently available.
Why the study?
Banxia Baizhu Tianma Tang (BBTT) is widely used for H-type hypertension, but evidence of its effectiveness remains unclear.
Does Banxia Baizhu Tianma Tang combined with conventional treatment reduce major adverse cardiac and cerebral events in patients with H-type hypertension?
Systematic Review
Does Banxia Baizhu Tianma Tang combined with conventional treatment reduce major adverse cardiac and cerebral events in patients with H-type hypertension?
This protocol outlines a systematic review to evaluate the efficacy and safety of Banxia Baizhu Tianma Tang combined with conventional therapy for H-type hypertension.
No results available from this protocol for Banxia Baizhu Tianma Tang in H-type hypertension; leaves open questions on efficacy and safety for cardiovascular outcomes.
BACKGROUND: H-type hypertension is a kind of cardiovascular disease that threatens human life and health seriously. Banxia Baizhu Tianma Tang (BBTT) has been used widely for H-type hypertension while its effective evidence is not clear. Hence, we provide a systematic review protocol to evaluate the efficacy and safety of BBTT in the treatment of H-type hypertension. METHODS: Nine databases including Cochrane Library, PubMed, EMBASE, WOS, Medline, CNKI, WangFang, CBM, and VIP will be searched from their inception to October 2019. All randomized controlled trials (RCTs) of BBTT for H-type hypertension will be included. The language is limited to Chinese and English. The primary outcome measure will be the major adverse cardiac and cerebral events (MACCE). The entire process will include study selection, data extraction, assessment of bias risk, data synthesis. Data analysis will be performed using RevMan V.5.3.5 (The Cochrane Collaboration, Oxford, UK). RESULTS: This study will evaluate the efficacy and safety of BBTT in the treatment of H-type hypertension from several aspects, including MACCE, blood pressure (BP), blood lipids, inflammation indicators and homocysteine (Hcy). CONCLUSION: This systematic review will provide evidence for determining whether or not BBTT is an effective and safe intervention for H-type hypertension. PROSPERO REGISTRATION NUMBER: PROSPERO CRD 42019131491.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) conducted a systematic review in H-type hypertension. Banxia Baizhu Tianma Tang (BBTT) vs. Conventional treatment (folic acid tablets and antihypertensives) was evaluated on Major adverse cardiac and cerebral events (MACCE). Banxia Baizhu Tianma Tang will be evaluated for its efficacy and safety in treating H-type hypertension in this systematic review protocol, with no clinical results currently available.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: